DUBLIN – Zealand Pharma A/S is walking away from its longstanding alliance with Sanofi SA in type 2 diabetes by selling off future income streams from lixisenatide, the glucagon-like-peptide-1 (GLP-1) agonist it discovered, to Royalty Pharma in a $205 million cash deal. Royalty, of New York, will receive sales royalties and potentially $85 million in future milestones from Paris-based Sanofi, although Copenhagen, Denmark-based Zealand will remain eligible for a final payment of up to $15 million, which it expects to receive in 2020. The trigger for that payment has not been disclosed.